Correction: Halofuginone inhibits radiotherapy-induced epithelial-mesenchymal transition in lung cancer

Yang Chen; Weishuai Liu; Peng Wang; Hailing Hou; Ningbo Liu; Linlin Gong; Youyou Wang; Kai Ji; Lujun Zhao; Ping Wang

doi:10.18632/oncotarget.25958

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Halofuginone inhibits radiotherapy-induced epithelial-mesenchymal transition in lung cancer

PDF | How to cite

Oncotarget. 2018; 9:31787-31787. https://doi.org/10.18632/oncotarget.25958

Metrics: PDF 1789 views | ?

Yang Chen^1,*, Weishuai Liu^2,*, Peng Wang³, Hailing Hou¹, Ningbo Liu¹, Linlin Gong¹, Youyou Wang¹, Kai Ji², Lujun Zhao¹ and Ping Wang¹

¹ Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China
² Department of Pain Management, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research, Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China
³ Department of Radiation Oncology, Peking University International Hospital, Beijing 102206, China
^* These authors have contributed equally to this work

Published: August 03, 2018

This article has been corrected: The correct author affiliation is given below:

Original article: Oncotarget. 2016; 7:71341-71352. DOI: https://doi.org/10.18632/oncotarget.11217.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25958

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: Halofuginone inhibits radiotherapy-induced epithelial-mesenchymal transition in lung cancer